Oral Mucositis (Ulcerative) Due to Radiation
Conditions
Keywords
Moist exposed burn ointment, Oral Mucositis Assessment Scale
Brief summary
This study aimed to assess the efficacy of MEBO® in the treatment of already established oral mucositis. This is a randomized controlled clinical trial. The study included 36 patients with established oral mucositis, divided into two groups. Patients were randomly allocated to either receive topically applied MEBO® ointment or Benzydamine Hydrochloride (Tantum Verde) mouthwash three times a day for two weeks. We assessed the World Health Organization mucositis score (WHO), the Oral Mucositis Assessment Scale (OMAS), and the Patient-Reported Oral Mucositis Symptom (PROMS) score at baseline, and after one and two weeks.
Interventions
MEBO® 0.25% Ointment (Gulf Pharmaceutical Industries) to be applied four times a day for two weeks
Tantum verde (EIPICO®) mouthwash. Patients were asked to swish it for at least five minutes, four times daily for two weeks.
Sponsors
Study design
Eligibility
Inclusion criteria
* Patients who later on during radiotherapy developed oral mucositis with a severity of WHO score II or more and were over 18 years were then included in the study and allocated to one of the treatment groups .
Exclusion criteria
* We excluded patients who were receiving any prophylactic agents and/or corticosteroids and those who would not sign the informed consent.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| WHO oral mucositis score | We assessed patients for the three outcomes at baseline, one week and at the end of the study period which is two weeks | The WHO oral mucositis score is an ordinal scale. The grades are as follows: Grade 0 is no mucositis, Grade 1 is soreness and/or erythema, Grade 2 involves ulcers and the ability to eat solids, Grade 3 indicates ulcers and the need for a liquid diet, and Grade 4 signifies ulcers with no possible oral alimentation |
Countries
Egypt